vs
CENTERSPACE（CSR）与Ginkgo Bioworks Holdings, Inc.（DNA）财务数据对比。点击上方公司名可切换其他公司
CENTERSPACE的季度营收约是Ginkgo Bioworks Holdings, Inc.的2.0倍（$66.6M vs $33.4M），CENTERSPACE同比增速更快（0.3% vs -23.8%），CENTERSPACE自由现金流更多（$64.3M vs $-47.7M），过去两年CENTERSPACE的营收复合增速更高（1.6% vs -6.2%）
Centerspace是一家专注于多户住宅物业持有、运营与开发的房地产投资企业，核心业务覆盖美国中西部及落基山西部区域，面向不同租户群体提供经济型及高端住宅选择，重视租户体验与资产长期价值增长。
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
CSR vs DNA — 直观对比
营收规模更大
CSR
是对方的2.0倍
$33.4M
营收增速更快
CSR
高出24.2%
-23.8%
自由现金流更多
CSR
多$112.0M
$-47.7M
两年增速更快
CSR
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $66.6M | $33.4M |
| 净利润 | $-18.4M | — |
| 毛利率 | 96.5% | — |
| 营业利润率 | -15.9% | -211.9% |
| 净利率 | -27.7% | — |
| 营收同比 | 0.3% | -23.8% |
| 净利润同比 | -262.9% | — |
| 每股收益（稀释后） | $-1.08 | $-1.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSRDNA
| Q4 25 | $66.6M | $33.4M | ||
| Q3 25 | $71.4M | $38.8M | ||
| Q2 25 | $68.5M | $49.6M | ||
| Q1 25 | $67.1M | $48.3M | ||
| Q4 24 | $66.4M | $43.8M | ||
| Q3 24 | $65.0M | $89.0M | ||
| Q2 24 | $65.0M | $56.2M | ||
| Q1 24 | $64.5M | $37.9M |
净利润CSRDNA
| Q4 25 | $-18.4M | — | ||
| Q3 25 | $53.8M | $-80.8M | ||
| Q2 25 | $-14.5M | $-60.3M | ||
| Q1 25 | $-3.7M | $-91.0M | ||
| Q4 24 | $-5.1M | — | ||
| Q3 24 | $-1.0M | $-56.4M | ||
| Q2 24 | $-1.3M | $-217.2M | ||
| Q1 24 | $-3.9M | $-165.9M |
毛利率CSRDNA
| Q4 25 | 96.5% | — | ||
| Q3 25 | 96.5% | — | ||
| Q2 25 | 96.5% | — | ||
| Q1 25 | 96.4% | — | ||
| Q4 24 | 96.5% | — | ||
| Q3 24 | 96.6% | — | ||
| Q2 24 | 96.6% | — | ||
| Q1 24 | 96.4% | — |
营业利润率CSRDNA
| Q4 25 | -15.9% | -211.9% | ||
| Q3 25 | — | -231.8% | ||
| Q2 25 | -9.9% | -132.1% | ||
| Q1 25 | 7.1% | -184.1% | ||
| Q4 24 | 4.3% | -236.3% | ||
| Q3 24 | 9.8% | -62.0% | ||
| Q2 24 | 11.1% | -396.7% | ||
| Q1 24 | 6.3% | -469.1% |
净利率CSRDNA
| Q4 25 | -27.7% | — | ||
| Q3 25 | 75.3% | -207.9% | ||
| Q2 25 | -21.2% | -121.6% | ||
| Q1 25 | -5.6% | -188.2% | ||
| Q4 24 | -7.6% | — | ||
| Q3 24 | -1.6% | -63.3% | ||
| Q2 24 | -2.0% | -386.4% | ||
| Q1 24 | -6.1% | -437.3% |
每股收益（稀释后）CSRDNA
| Q4 25 | $-1.08 | $-1.41 | ||
| Q3 25 | $3.19 | $-1.45 | ||
| Q2 25 | $-0.87 | $-1.10 | ||
| Q1 25 | $-0.22 | $-1.68 | ||
| Q4 24 | $-0.31 | $-1.91 | ||
| Q3 24 | $-0.40 | $-1.08 | ||
| Q2 24 | $-0.19 | $-4.23 | ||
| Q1 24 | $-0.37 | $-3.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.8M | $422.6M |
| 总债务越低越好 | $1.0B | — |
| 股东权益账面价值 | $719.2M | $508.6M |
| 总资产 | $1.9B | $1.1B |
| 负债/权益比越低杠杆越低 | 1.42× | — |
8季度趋势，按日历期对齐
现金及短期投资CSRDNA
| Q4 25 | $12.8M | $422.6M | ||
| Q3 25 | $12.9M | $495.5M | ||
| Q2 25 | $12.4M | $559.4M | ||
| Q1 25 | $11.9M | $325.3M | ||
| Q4 24 | $12.0M | $561.6M | ||
| Q3 24 | $14.5M | $616.2M | ||
| Q2 24 | $14.3M | $730.4M | ||
| Q1 24 | $12.7M | $840.4M |
总债务CSRDNA
| Q4 25 | $1.0B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $955.5M | — | ||
| Q4 24 | $955.4M | — | ||
| Q3 24 | $921.3M | — | ||
| Q2 24 | $931.7M | — | ||
| Q1 24 | $929.1M | — |
股东权益CSRDNA
| Q4 25 | $719.2M | $508.6M | ||
| Q3 25 | $748.6M | $559.8M | ||
| Q2 25 | $710.1M | $613.0M | ||
| Q1 25 | $636.8M | $647.4M | ||
| Q4 24 | $752.0M | $716.1M | ||
| Q3 24 | $672.5M | $797.9M | ||
| Q2 24 | $680.7M | $833.1M | ||
| Q1 24 | $688.1M | $987.3M |
总资产CSRDNA
| Q4 25 | $1.9B | $1.1B | ||
| Q3 25 | $2.1B | $1.2B | ||
| Q2 25 | $2.0B | $1.2B | ||
| Q1 25 | $1.9B | $1.3B | ||
| Q4 24 | $1.9B | $1.4B | ||
| Q3 24 | $1.9B | $1.5B | ||
| Q2 24 | $1.9B | $1.6B | ||
| Q1 24 | $1.9B | $1.6B |
负债/权益比CSRDNA
| Q4 25 | 1.42× | — | ||
| Q3 25 | 1.53× | — | ||
| Q2 25 | 1.57× | — | ||
| Q1 25 | 1.50× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.37× | — | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 1.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $98.5M | $-47.7M |
| 自由现金流经营现金流 - 资本支出 | $64.3M | $-47.7M |
| 自由现金流率自由现金流/营收 | 96.5% | -142.8% |
| 资本支出强度资本支出/营收 | 51.3% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $125.9M | — |
8季度趋势，按日历期对齐
经营现金流CSRDNA
| Q4 25 | $98.5M | $-47.7M | ||
| Q3 25 | $35.1M | $-31.6M | ||
| Q2 25 | $25.3M | $-40.3M | ||
| Q1 25 | $25.4M | $-51.5M | ||
| Q4 24 | $98.2M | $-42.4M | ||
| Q3 24 | $32.3M | $-103.5M | ||
| Q2 24 | $22.9M | $-84.4M | ||
| Q1 24 | $24.4M | $-89.3M |
自由现金流CSRDNA
| Q4 25 | $64.3M | $-47.7M | ||
| Q3 25 | $25.7M | — | ||
| Q2 25 | $15.5M | $-40.3M | ||
| Q1 25 | $20.4M | $-59.1M | ||
| Q4 24 | $41.6M | $-56.1M | ||
| Q3 24 | $20.5M | $-118.6M | ||
| Q2 24 | $9.1M | $-111.4M | ||
| Q1 24 | $2.6M | $-96.0M |
自由现金流率CSRDNA
| Q4 25 | 96.5% | -142.8% | ||
| Q3 25 | 36.0% | — | ||
| Q2 25 | 22.7% | -81.2% | ||
| Q1 25 | 30.4% | -122.4% | ||
| Q4 24 | 62.6% | -128.0% | ||
| Q3 24 | 31.5% | -133.2% | ||
| Q2 24 | 14.0% | -198.2% | ||
| Q1 24 | 4.0% | -252.9% |
资本支出强度CSRDNA
| Q4 25 | 51.3% | 0.0% | ||
| Q3 25 | 13.1% | 0.0% | ||
| Q2 25 | 14.2% | 0.1% | ||
| Q1 25 | 7.5% | 15.8% | ||
| Q4 24 | 85.3% | 31.3% | ||
| Q3 24 | 18.2% | 16.9% | ||
| Q2 24 | 21.2% | 48.1% | ||
| Q1 24 | 33.8% | 17.7% |
现金转化率CSRDNA
| Q4 25 | — | — | ||
| Q3 25 | 0.65× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSR
| Multi Family Residential | $57.3M | 86% |
| Other | $8.1M | 12% |
| Other Property Revenue | $1.2M | 2% |
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
